Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Trial Profile

Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms CheckMate 800
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Aug 2017 Planned primary completion date changed from 19 Nov 2017 to 28 Dec 2017.
    • 01 Aug 2017 Planned primary completion date changed from 18 Mar 2018 to 19 Nov 2017.
    • 19 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 18 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top